These are top 10 stocks traded on the Robinhood UK platform in July
NeoGenomics Inc (NASDAQ:NEO). shares have touched a 52-week low, dipping to $8.9, representing a steep 42.8% decline year-to-date as the company grapples with market headwinds. According to InvestingPro data, the company maintains strong revenue growth of 11.7%, despite current challenges. The stock’s latest price level reflects a significant downturn from its previous performance, marking a stark contrast to the more robust valuations it has seen in the past. Over the past year, NeoGenomics has seen its stock value decrease by 38.67%, a substantial decline that underscores the challenges the company has faced in maintaining its market position. Investors are closely monitoring the stock for signs of a turnaround, with analyst price targets ranging from $16 to $26, suggesting potential upside. InvestingPro analysis reveals 6 additional key insights about NeoGenomics’ future prospects, available exclusively to subscribers.
In other recent news, NeoGenomics reported its fourth-quarter 2024 earnings, revealing a mixed financial performance. The company exceeded earnings per share (EPS) expectations by reporting $0.04 compared to the forecast of $0.03. However, revenue fell short of expectations, coming in at $172 million against a forecast of $173.05 million. For the full year 2024, NeoGenomics experienced a 17% decline in revenue, totaling $476 million, but saw a 70% increase in adjusted EBITDA, reaching $64 million. Benchmark has maintained a Hold rating on NeoGenomics shares, projecting total revenue for 2025 in the range of $735-745 million. Piper Sandler reiterated an Overweight rating with an $18 price target, expressing confidence in the management team following significant executive changes. Tony Zook has been appointed as the new CEO, succeeding Chris Smith, who will remain in an advisory role. The company also announced the acquisition of Pathline LLC to strengthen its presence in the Northeast and enhance its service offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.